The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches

Inflammatory Bowel Disease

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

Lancet Gastroenterol Hepatol.

Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR

doi: 10.1016/S2468-1253

Inflammatory Bowel Disease

Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease

Eur J Gastroenterol Hepatol.

Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL

doi: 10.1097/

RECOMMENDED

Inflammatory Bowel Disease

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease

J Crohns Colitis.

Chaparro M, Garre A, Guerra Veloz MF, Vázquez JM, De Castro ML, Leo E, Rodriguez E, Carbajo AY, Riestra S, Jiménez I, Calvet X, Bujanda L, Rivero M, Gomollón F, Benítez JM, Bermejo F, Alcaide N, Gutiérrez A, Mañosa M, Iborra M, Lorente R, Rojas-Feria M, Barreiro-de Acosta M, Kolle L, Van Domselaar M, Amo V, Argüelles F, Ramírez E, Morell A, Bernardo D, Gisbert JP

doi: 10.1093/ecco-jcc/jjz070.

Inflammatory Bowel Disease

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial

J Intern Med.

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KE, Tveit KS, Lorentzen M, Berset IP, Fevang BT, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK

doi: 10.1111/joim.12880.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Inflammatory Bowel Disease

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Eur J Gastroenterol Hepatol.

Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM, Swiss IBD Cohort Study Group

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study

BMC Gastroenterol.

Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E

doi: 10.1186/s12876-019-1110-1.

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

Inflammatory Bowel Disease

Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: Short-term experience from a single tertiary clinical center

J Crohns Colitis.

Lukas M, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N, Hruba V, Duricova D, Lukas M

doi: 10.1093/ecco-jcc/jjaa001.

Related content

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: Short-term experience from a single tertiary clinical center